Palvella Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good morning and thank you for being with us here today. My name is Elizabeth Webster, and I'm on the biotech equity research team at Goldman Sachs. I'm joined by Wes Kaupinen, the Founder and CEO of Palvella Therapeutics.
So to start, Wes, help us level set here and provide a brief intro to the company and the QTORIN platform and your near-term catalyst path.
Great. Well, thank you, Elizabeth, for having me today at the Goldman Conference. I'd like to start with the name Palvella. Palvella in Finnish means to serve. So the mission of our company is to serve patients that have serious rare skin diseases and vascular malformations that currently have no FDA-approved therapies.
Our corporate strategy can be summed up in a word, which is first. We want to be first for patients. Who do not have a single FDA-approved treatment. And our goal is to not only to develop but also to commercialize on a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
